Published in final edited form as:

Cancer Res. 2013 November 1; 73(21): . doi:10.1158/0008-5472.CAN-13-0681.

Mutationally Activated PIK3CA^{H1047R} Cooperates With BRAF^{V600E} To Promote Lung Cancer Progression

Christy L. Trejo^{1,2,‡}, Shon Green^{1,2}, Victoria Marsh^{1,2,†}, Eric A. Collisson³, Gioia Iezza⁴, Wayne A. Phillips⁵, and Martin McMahon^{1,2,¶}

¹Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco CA 94158, USA

²Dept. of Cell & Molecular Pharmacology, University of California, San Francisco CA 94158, USA

³Dept. of Hematology & Oncology, University of California, San Francisco CA 94158, USA

⁴Dept. of Pathology, University of California, San Francisco CA 94158, USA

⁵Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia

Abstract

Adenocarcinoma of the lung, a leading cause of cancer death, frequently displays mutational activation of the *KRAS* proto-oncogene but, unlike lung cancers expressing mutated *EGFR*, *ROS1* or *ALK*, there is no pathway-targeted therapy for patients with *KRAS* mutated lung cancer. In pre-clinical models, expression of oncogenic *KRAS*^{G12D} in the lung epithelium of adult mice initiates development of lung adenocarcinoma through activation of downstream signaling pathways. By contrast, mutationally activated BRAF^{V600E}, a *KRAS* effector, fails to initiate lung carcinogenesis despite highly efficient induction of benign lung tumorigenesis. To test if PI3 -kinase- (PIK3CA), another *KRAS* effector, might cooperate with oncogenic BRAF^{V600E} to promote lung cancer progression, we employed mice carrying a conditional allele of *Pik3ca* that allows conversion of the wild-type catalytic subunit of PIK3CA to mutationally activated PIK3CA^{H1047R}. Whereas expression of PIK3CA^{H1047R} in the lung epithelium, either alone or in combination with PTEN silencing, was without phenotype, concomitant expression of BRAF^{V600E} and PIK3CA^{H1047R} led to dramatically decreased tumor latency and increased tumor burden compared to BRAF^{V600E} alone. Most notably, co-expression of BRAF^{V600E} and PIK3CA^{H1047R} elicited lung adenocarcinomas in a manner reminiscent of the effects of *KRAS*^{G12D}. These data emphasize a role for PI3 -kinase signaling, not in lung tumor initiation *per se*, but in both the rate of tumor growth and the propensity of benign lung tumors to progress to a malignant phenotype. Finally, biological and biochemical analysis of BRAF^{V600E}/PIK3CA^{H1047R} expressing mouse lung cancer cells revealed mechanistic clues as to cooperative regulation of the cell division cycle and apoptosis by these oncogenes.

INTRODUCTION

Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality (1). Recently identified mutations in proto-oncogenes in NSCLC have provided strategies for the deployment of pathway-targeted therapies (2). However, despite the success of such agents

[¶]Corresponding author: Diller Cancer Research Building, MC-0128, 1450 Third Street, Room HD-365, University of California, San Francisco, CA 94158, USA, Phone (415) 502 5829, FAX: (415) 502 3179, mcmahon@cc.ucsf.edu.

[‡]Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037.

[†]Pathophysiology and Repair Division, Cardiff School of Biosciences, Cardiff, U.K.

in the treatment of genetically-defined subsets of lung cancer, most NSCLC patients do not have recourse to the use of such agents.

Of the proto-oncogenes mutated in NSCLC, *KRAS* remains the most common (25%) and the most pharmacologically intractable (2). Consequently, attention has turned to inhibiting key downstream signaling pathways required for maintenance of *KRAS* mutated NSCLC. Moreover, *KRAS* effectors such as BRAF, PI3-kinase and AKT are also directly implicated as *bona fide* human lung cancer genes (2, 3, 4, 5). However, a key outstanding question is, what *KRAS*^{G12D} regulated pathways are essential for lung carcinogenesis in GEM models? Although *KRAS*^{G12D}-driven tumors are MEK1/2 dependent, expression of BRAF^{V600E} in the lung epithelium elicits benign lung tumors that rarely progress to malignancy due to a senescence-like growth arrest (6, 7, 8). By contrast, although transgenic expression of mutationally activated PIK3CA^{H1047R} in the lung epithelium was reported to promote lung tumorigenesis, combined inhibition of PI3-kinase/mTorC had no effect on established *KRAS*^{G12D}-initiated lung tumors (9). Consequently, we tested whether mutationally activated BRAF^{V600E} and PIK3CA^{H1047R} might cooperate in promoting lung carcinogenesis using GEM models (6, 11).

Perhaps surprisingly, we could not substantiate reports that PIK3CA^{H1047R} can initiate lung tumorigenesis. However, concomitant expression of both BRAF^{V600E} and PIK3CA^{H1047R} led to rapid onset of lung tumorigenesis with evidence of malignant progression observed six months after tumor initiation. The cooperative effects of PIK3CA^{H1047R} *in vivo* were AKT dependent and were modeled *in vitro*. Finally, we demonstrate that both BRAF^{V600E} and PIK3CA signaling is necessary for proliferation and survival of BRAF^{V600E}/PIK3CA^{H1047R} expressing lung cancer cells and demonstrate that these pathways cooperatively regulate the cell division cycle and apoptosis.

RESULTS

Expression of PIK3CA^{H1047R} combined with PTEN silencing fails to induce lung tumors in mice

To test whether PIK3CA^{H1047R} could initiate lung tumorigenesis, we employed *Pik3ca*^{lat-H1047R} mice (*Pik3ca*^{lat}) carrying a modified *Pik3ca* allele that expresses normal PIK3CA prior to Cre-mediated recombination after which PIK3CA^{H1047R} is expressed under control of the gene's chromosomal regulatory elements (9, 11). Cre-mediated genetic alterations were initiated using an adenovirus encoding Cre recombinase (Ad-Cre) (6). Since expression of PIK3CA^{H1047R} from a single allele might be insufficient for lung tumorigenesis, we generated mice with every possible heterozygous or homozygous combination of *Pik3ca*^{lat} in combination with a conditional null allele of *Pten* (*Pten*^{lox}) (12).

The lungs of adult mice of the various *Pik3ca*^{lat}/*Pten*^{lox} genotypes were infected with Ad-Cre and euthanized for analysis three, six or 12 months post-infection. As a control for successful tumor induction, BRAF^{V600E} expression was initiated in the lung epithelium of *BRaf*^{CA} mice, which developed benign lung adenomas at high multiplicity requiring euthanasia ~12 weeks post-initiation (Fig. 1A, right panel). By contrast, we failed to detect lung tumors in mice carrying conditional alleles of *Pik3ca* or *Pten*, either alone or in combination, at three or six months after Ad-Cre infection (Fig. 1A, left and middle panels). That PTEN silencing was insufficient for lung tumorigenesis was consistent with previous observations, but the lack of lung tumorigenesis in the compound *Pik3ca*^{lat}/*Pten*^{lox} mice was surprising (13). At 12 months we detected benign adenomas in *Pik3ca*^{lat/lat}; *Pten*^{lox/lox} mice however these were rare (< one tumor/mouse). Most of these tumors stained positive for PTEN expression and negative for phospho (p)-AKT suggesting that they may be spontaneously arising lung tumors unrelated to mouse genotype. However, we also detected

very rare lung tumors in *Pik3ca^{lat/lat}; Pten^{lox/lox}* mice that stained brightly for pAKT and may therefore due to this combination of genetic modifications (Fig. 1T). Immunofluorescence analysis of Ad-Cre infected *Pik3ca^{lat}* or *Pik3ca^{lat/lat}* mice failed to detect evidence of cells with pAKT or Ki67 expression above that detected in normal mouse lung (Fig. 1F–M). However, in *Pik3ca^{lat}* mice carrying either one or two *Pten^{lox}* alleles, small numbers of airway epithelial hyperplasias were detected (Fig. 1N–U). Most prevalent in *Pik3ca^{lat/lat}; Pten^{lox/lox}* mice, these lesions comprised small numbers of cells that stained negative for PTEN and positive for pAKT, with the strongest pAKT signal detected in lesions in *Pik3ca^{lat/lat}; Pten^{lox/lox}* mice (Fig. 1R). These lesions were 50µm in diameter and not proliferative (Fig. 1S). Hence, by contrast to the effects of KRAS^{G12D} or BRAF^{V600E}, there was no combination of *Pik3ca^{lat}* and *Pten^{lox}* that elicited lung tumors in mice within 6 months after Ad-Cre (6, 9, 14).

PIK3CA^{H1047R} dramatically accelerates BRAF^{V600E} driven lung tumorigenesis

To determine if PIK3CA^{H1047R} cooperates with BRAF^{V600E} in lung tumorigenesis, we infected adult *BRaf^{CA}* or compound *BRaf^{CA}; Pik3ca^{lat}* mice with either 5x10⁶ or 10⁷ pfu Ad-Cre. Kaplan-Meier survival analysis of mice infected with 5x10⁶ pfu Ad-Cre indicated that all *BRaf^{CA}; Pik3ca^{lat}* mice reached end-stage by ~50 days based on their body conditioning score, a time at which all *BRaf^{CA}* mice remained healthy (Fig. 2A) (15). Overall, *BRaf^{CA}* mice lived twice as long as *BRaf^{CA}; Pik3ca^{lat}* littermates after initiation (median survival 100 vs. 39 days, $p = 1.25 \times 10^{-5}$, Fig. 2B). Furthermore, three weeks after infection with 10⁷ pfu Ad-Cre, many *BRaf^{CA}; Pik3ca^{lat}* mice displayed labored breathing and reduced body weight indicating onset of lethal lung tumorigenesis at which time representative mice were euthanized for necropsy (Fig. 2B). Compared to control *BRaf^{CA}* mice, *BRaf^{CA}; Pik3ca^{lat}* mice presented with more tumors (96 vs. 54, $p=0.025$) and BRAF^{V600E}/PIK3CA^{H1047R} expressing tumors were larger than their BRAF^{V600E} expressing counterparts (52,516 µm² vs. 6,782.5µm², $p=0.004$, Figs. 2B&C). Three weeks post-initiation, BRAF^{V600E}/PIK3CA^{H1047R} expressing lung lesions manifested as large adenomas, whereas *BRaf^{CA}* mice displayed only alveolar and/or airway hyperplasias (Figs. 2B&C). Overall, *BRaf^{CA}; Pik3ca^{lat}* mice displayed a 14-fold higher tumor burden at three weeks post-initiation compared to *BRaf^{CA}* mice (16.8% vs. 1.2%, $p=0.01$, Fig. 2C).

PTEN silencing enhances BRAF^{V600E}-induced lung tumorigenesis

To complement analysis of the effects of PIK3CA^{H1047R} on BRAF^{V600E}-induced lung tumorigenesis, we tested if deregulation of PI3-kinase signaling through PTEN silencing might have similar effects. Indeed, this is a combination of alterations commonly found in human melanoma and which cooperate in GEM models of the disease (5, 16). We infected *BRaf^{CA}*, *BRaf^{CA}; Pik3ca^{lat/+}* or compound *BRaf^{CA}; Pten^{lox/lox}* with 10⁶ pfu Ad-Cre with mice euthanized four weeks after initiation. Compared to control *BRaf^{CA}* mice, *BRaf^{CA}; Pik3ca^{lat}* and *BRaf^{CA/+}; Pten^{lox/lox}* mice displayed a 10-fold and a 4-fold increase in overall tumor burden respectively (2.8% vs. 31.2% vs. 10.8%, Figs. 3A & B). Whereas most lung tumor cells arising in *BRaf^{CA}* mice displayed readily detectable PTEN expression, the vast majority of tumor cells in *BRaf^{CA}; Pten^{lox/lox}* mice were PTEN negative (Fig 3C). These data indicate that the statistically significant difference between lung tumorigenesis in *BRaf^{CA}; Pik3ca^{lat}* vs. *BRaf^{CA/+}; Pten^{lox/lox}* mice is not due to inefficient PTEN silencing. Overall, these data support the hypothesis that activation of PI3-kinase signaling, either by co-expression of PIK3CA^{H1047R} or PTEN silencing, cooperates with BRAF^{V600E} in lung tumorigenesis (13).

Pharmacological blockade of MEK or AKT prevents the growth of BRAF^{V600E}/PIK3CA^{H1047R} lung tumors

To assess the role of downstream signaling components on the cooperation between BRAF^{V600E} and PIK3CA^{H1047R}, we employed pharmacological inhibitors of either MEK1/2 (PD325901) or AKT (MK-2206) (17, 18). These agents are non-substrate competitive, allosteric inhibitors with high specificity and selectivity. *BRaf^{CA}* or *BRaf^{CA}*; *Pik3ca^{lat}* mice were infected with 10⁶ Ad-Cre and then separated into two groups for treatment with either vehicle control or MK-2206 (120 mg/kg, q.d., po) to inhibit AKT for an additional 4–5 weeks at which time mice were euthanized.

MK-2206 treatment had no effect on BRAF^{V600E}-initiated lung tumor burden (vehicle - 25% vs. MK-2206 - 22%, $p=0.63$, Fig. S1A). By contrast, consistent with previous results, MEK1/2 inhibition largely abolished BRAF^{V600E}-induced lung tumorigenesis (not shown) (6, 7). These data strongly suggest that BRAF^{V600E}-induced lung tumors are AKT independent for their initial growth.

By contrast to BRAF^{V600E} driven tumors, MK-2206 had a significant effect on BRAF^{V600E}/PIK3CA^{H1047R} driven lung tumorigenesis (Figs. 4A&B). Although four weeks of MK-2206 dosing had no effect on overall tumor number (vehicle = 31.8 vs. MK-2206 = 28.7; $p=0.76$), both tumor size (vehicle = 121,413 μm^2 vs. MK-2206 = 30,083 μm^2 , $p<0.0001$) and overall tumor burden (vehicle = 20.7%, MK-2206 = 5%, $p=0.004$), were significantly reduced following AKT inhibition (Figs. 4B). Indeed, tumor sizes and overall tumor burden that developed in *BRaf^{CA}*; *Pik3ca^{lat}* mice in the presence of MK-2206 were roughly equivalent to that observed in *BRaf^{CA}* mice. These data support the hypothesis that AKT activity is required for the cooperation between BRAF^{V600E} and PIK3CA^{H1047R} in lung tumorigenesis but largely dispensable for the growth of BRAF^{V600E}-induced lung tumors. Inhibition of pS473-AKT by MK-2206 was confirmed by immunoblot analysis of lysates of BRAF^{V600E} or BRAF^{V600E}/PIK3CA^{H1047R} expressing lung tumors treated with either vehicle or MK-2206 two hours prior to euthanasia (Figs. S1B & S1C, respectively).

Previous studies have indicated the exquisite sensitivity of BRAF^{V600E} driven lung tumors to MEK1/2 inhibition with PD325901 (6, 7). However, analysis of lung, pancreas and colon cancer cell lines suggest that PI3 -kinase signaling, either by mutation of *PIK3CA* or *PTEN* silencing, can render cells less sensitive to MEK inhibition possibly by sustaining the expression of D-type cyclins (19, 20). Hence, we sought to determine if BRAF^{V600E}/PIK3CA^{H1047R} lung tumors remained sensitive to MEK1/2 inhibition *in vivo*. Lung tumors were initiated in *BRaf^{CA}*; *Pik3ca^{lat}* mice and two weeks later mice were dosed with vehicle or PD325901 (12.5mg/kg, q.d. po) for a further four weeks at which time mice were euthanized (Figs. 4A&B). Compared to controls, MEK1/2 inhibitor treated mice displayed a 15-fold reduction in tumor number (31.8 vs. 2.0, $p=0.005$). Lesions detected in PD325901 treated *BRaf^{CA}*; *Pik3ca^{lat}* mice were largely small alveolar or airway hyperplasias and no fully formed adenomas were present in these mice. This resulted in a ~12-fold reduction in average tumor size (vehicle = 121,413 μm^2 vs. PD325901 = 10,914 μm^2 for drug treated mice, $p<0.0001$) and a >20,000-fold reduction in overall tumor burden (vehicle = 20.7% vs. PD325901 = 0.001%, $p=0.0004$) compared to controls (Figure 4B). Consequently, these data indicate that BRAF^{V600E}/PIK3CA^{H1047R} lung tumors remain sensitive to the anti-tumor effects of MEK1/2 inhibition and highlight the central importance of BRAF^{V600E} MEK ERK signaling in the growth of BRAF^{V600E}/PIK3CA^{H1047R}-induced lung tumors.

Enhanced therapeutic benefit of combined BRAF^{V600E} plus PIK3CA^{H1047R} inhibition against BRAF^{V600E}/PIK3CA^{H1047R} expressing lung tumors

To examine the requirement for sustained signaling in maintenance of BRAF^{V600E}/PIK3CA^{H1047R} expressing lung tumors, we initiated tumorigenesis in 34 *BRaf^{CA}; Pik3ca^{lat}* mice and monitored them for five weeks until they were close to end-stage. At this time two mice were euthanized with the remaining mice divided into four cohorts for the following interventions: 1. No treatment; 2. Class 1 PI3-kinase inhibitor (BKM-120, 60mg/kg, q.d., po); 3. BRAF^{V600E} inhibitor (LGX-818, 30mg/kg, q.d., po) or; 4. Combination of BKM-120 and LGX-818 (60 and 30mg/kg respectively, q.d., po) (21, 22). Drug benefit was assessed by Kaplan-Meier analysis with mice euthanized when their body conditioning score (BCS) was 2 (15) (Fig. 4C). In addition we monitored mouse body weight, which correlates with changes in tumor burden (Fig. 4D).

There was no statistical difference in survival between untreated (n=6) or BKM-120 treated (n=8) mice, all of which lost weight requiring euthanasia within five days after dosing (Figs. 4C&D). By contrast, mice treated with LGX-818 (n=8) or combined LGX-818 plus BKM-120 (n=8) displayed increased survival (Fig. 4C) such that no mice in the combination arm required euthanasia. Although LGX-818 treated mice continued to lose weight, this was at reduced rate and only 1/8 mice developed end-stage disease. Finally, mice treated with combined LGX-818 plus BKM-120 displayed immediate signs of improvement in their BCS that continued throughout the treatment period (Fig. 4D).

Analysis of mouse lungs from each group indicated that untreated and BKM-120 treated mice displayed a substantial tumor burden (average of ~28% and ~23%) with no difference between them, consistent with the lack of benefit afforded by BKM-120 (Figs. 4E&F). By contrast, LGX-818 treated mice displayed reduced tumor burden (~10%) compared to control or BKM-120 treated mice. The therapeutic benefit of LGX-818 treated mice was further enhanced by combination with BKM-120 (~3% tumor burden) consistent with the survival and health benefits afforded these mice. Taken together, combined blockade of BRAF^{V600E} and PIK3CA^{H1047R} signaling in BRAF^{V600E}/PIK3CA^{H1047R} expressing lung tumors was superior to blockade of BRAF^{V600E} or PIK3CA^{H1047R} alone.

PIK3CA^{H1047R} promotes malignant progression of BRAF^{V600E}-induced tumors

KRAS^{G12D}-induced lung tumorigenesis in GEM models depends on RAF MEK ERK, PI3-kinase, RAC1 and NF- κ B signaling (7, 9, 23–26). However, to date, activation of single nodes downstream of KRAS.GTP fails to recapitulate the malignant progression displayed by KRAS^{G12D}-initiated lung tumors. Although BRAF^{V600E} induces benign lung tumors, such lesions are low grade and fail to progress to lung cancer (6, 7). As demonstrated here, although PIK3CA^{H1047R} is unable to initiate lung tumorigenesis, it promotes the growth BRAF^{V600E}-initiated lung tumors. This prompted us to evaluate whether BRAF^{V600E} and PIK3CA^{H1047R} might cooperate for malignant lung cancer progression. To that end, tumors were initiated in either *BRaf^{CA}* or *BRaf^{CA}; Pik3ca^{lat}* mice (5x10⁵ pfu Ad-Cre) with mice euthanized 25 weeks later for evaluation (7, 27).

By contrast with early time points, overall tumor number was not different between *BRaf^{CA}* and *BRaf^{CA}; Pik3ca^{lat}* mice with an average of 30 tumors per lobe recorded in both genotypes (Figs. 5A&B). However, individual lung tumors in *BRaf^{CA}; Pik3ca^{lat}* mice were larger than those in *BRaf^{CA}* mice (35,000 μ m² vs. 5,000 μ m², $p=0.0005$, Fig. 5B). Differences in tumor size were reflected by overall increased tumor burden in *BRaf^{CA}; Pik3ca^{lat}* mice (24% vs. 6%, $p=0.0001$, Fig. 5B). These data suggest that PIK3CA^{H1047R} does not influence the frequency of BRAF^{V600E} initiated cells in the lung epithelium, but

decreases the latency period prior to tumorigenesis and also increases their overall proliferative potential.

One possible explanation for the larger tumors observed in *BRAF^{CA}; Pik3ca^{lat}* mice is that each tumor arises in a polyclonal manner from more than one initiated cell. To test the clonality of *BRAF^{V600E}/PIK3CA^{H1047R}* lung tumors we generated *BRAF^{CA}; Pik3ca^{lat}* mice containing the “Confetti” reporter (*Gt(ROSA)26Sor^{tm1}(CAG-Brainbow2.1)Cre*, *R26^{Confetti}* hereafter) (Supp. Fig. 2) (28). The action of Cre on the *R26^{Confetti}* reporter elicits a recombination event that stochastically places one of four different fluorescent proteins (FP) downstream of the CAG promoter. Hence, if *BRAF^{V600E}/PIK3CA^{H1047R}*-induced lung tumors are clonally derived, each tumor should express a single FP. However, if tumors are polyclonal in origin, they will contain a mixture of cells with different FP expression. *BRAF^{CA}; Pik3ca^{lat}, R26^{Confetti}* mice were infected with 10⁷ pfu Ad-Cre with lung tumors analyzed 9 weeks later. Individual *BRAF^{V600E}/PIK3CA^{H1047R}* lung tumors were uniformly positive for a single FP, indicating that each tumor is clonally derived from a single initiated cell (Supp. Fig. 2).

To assess malignant progression, we employed a grading scheme based on the classification of lung lesions in GEM models to assess the grade of >250 tumors from mice of each genotype (Fig. 5C and Supp. Figs. 3A&B) (14, 27). Hyperplasia was designated Grade 1, benign adenomas as Grade 2, larger adenomas as Grade 3 and adeno-squamous or adenocarcinomas as Grade 4. *BRAF^{V600E}*-induced lung lesions were predominantly Grade 1 or 2 with rare examples of Grade 3 detected. By contrast, *BRAF^{V600E}/PIK3CA^{H1047R}*-induced lesions were generally Grade 2 or 3 adenomas but ~3% of tumors were malignant Grade 4 adeno-squamous or adenocarcinoma lesions. These data indicate that *BRAF^{V600E}* cooperates with *PIK3CA^{H1047R}* to both accelerate early-stage lung tumorigenesis and to promote late-stage malignant progression (14).

To determine if the cell of origin might influence the spectrum of lung tumors initiated in these mice, we employed adenovirus vectors with lung cell specific expression of Cre recombinase (29). Ad-SPC-Cre, Ad-CCSP-Cre and Ad-CGRP-Cre direct Cre expression to Alveolar type II pneumocytes, Clara or neuroendocrine cells respectively. Of these, we noted that Ad-SPC-Cre was the most potent inducer of lung tumorigenesis in either *BRAF^{CA}* or *BRAF^{CA}; Pik3ca^{lat}* mice and was equivalent in potency to Ad-CMV-Cre. Moreover, tumors emerging in mice initiated with either Ad-CCSP-Cre or Ad-CGRP-Cre, which were less potent in inducing lung tumorigenesis, displayed the cuboidal morphology and expression of SP-C characteristic of AT2 cells (data not shown).

In these experiments we assessed tumor grade at 22 weeks in groups of *BRAF^{CA}* or *BRAF^{CA}; Pik3ca^{lat}* mice initiated with Ad-SPC-Cre to confirm the ability of *PIK3CA^{H1047R}* to promote malignant progression of *BRAF^{V600E}*-initiated lung tumors (Supp. Fig. 4). As before, the majority of *BRAF^{V600E}* expressing lung tumors were small, grade 2 adenomas. By contrast, >50% of lung tumors in the *BRAF^{CA}; Pik3ca^{lat}* mice were high-grade adenomas (Grade 3) and 8.5% were either grade 4 adeno-squamous cancers or adenocarcinomas confirming observations made with Ad-CMV-Cre (30).

TP53 constrains malignant progression of *BRAF^{V600E}/PIK3CA^{H1047R}* lung tumors

TP53 mutations frequently coexist with mutations in *KRAS*, *BRAF* or *PIK3CA* mutations in human lung adenocarcinomas and *TP53* mutation or silencing promotes malignant progression of either *KRAS^{G12D}* or *BRAF^{V600E}*-driven lung tumors (6, 14). Consequently, we determined if *TP53* loss would enhance lung tumorigenesis initiated by combined expression of *BRAF^{V600E}* and *PIK3CA^{H1047R}*. Tumorigenesis was initiated in a *BRAF^{CA/CA}; Pik3ca^{lat}, Trp53^{lox/lox}* mouse with a *BRAF^{CA}; Trp53^{lox/lox}* mouse as a littermate

control. Within four weeks the former mouse displayed end-stage disease requiring euthanasia. Whereas the *BRAF*^{CA}; *Trp53*^{lox/lox} mouse had a tumor burden of 0.2% made up of mainly small hyperplasias with a solitary benign adenoma detected (Supp. Fig. 5A), the *BRAF*^{CA/CA}; *Pik3ca*^{lat}; *Trp53*^{lox/lox} mouse had a tumor burden of 41% made up of high grade, anaplastic adenocarcinoma. Moreover, these high-grade tumors stained positive for Vimentin, a marker of epithelial-mesenchymal transition, lacked TTF-1/NKX2-1 expression, a marker of the distal lung epithelium and displayed a high proliferative index (Ki67, Supp. Fig. 5B). Similar results were obtained using a second *BRAF*^{CA/+}; *Pik3ca*^{lat}; *Trp53*^{lox/lox} mouse.

PIK3CA^{H1047R} promotes BRAF^{V600E}-induced oncogenic transformation *in vitro*

An advantage of GEM models cancer is the ability to engineer defined genetic alterations and then generate cell lines for *in vitro* analysis. To that end, we generated *BRAF*^{V600E}/*TP53*^{Null} and *BRAF*^{V600E}/*PIK3CA*^{H1047R}/*TP53*^{Null} mouse lung cancer derived cell lines (BT and BPT cells hereafter) from suitably manipulated mice (7).

Since BT cells displayed a limited capacity for anchorage independent growth we engineered them to express either mCherry (control), *PIK3CA*^{H1047R} or a myristoylated, constitutively activated AKT1 (M⁺AKT1) to test whether activation of PI3 -kinase signaling might cooperate with *BRAF*^{V600E} to influence the behavior of these cells (Fig. 6). Cell extracts were analyzed by immunoblotting for the activation status of key nodes in the PI3 -kinase signaling pathway (Fig. 6A and Supp. Fig. 8A). Compared to control, cells expressing either *PIK3CA*^{H1047R} or M⁺AKT1 displayed elevated pPRAS40 and pRP-S6 while M⁺AKT1 expressing cells displayed elevated levels of pAKT, p4E-BP1, pFOXO1 and pGSK3 . *PIK3CA*^{H1047R} and M⁺AKT1 cells also showed a decrease in p27^{KIP1} expression. Consistent with the ability of *PIK3CA*^{H1047R} to cooperate with *BRAF*^{V600E} in lung tumorigenesis *in vivo*, expression of either *PIK3CA*^{H1047R} or M⁺AKT1 led to increased anchorage-independent colony formation *in vitro* (Fig. 6B). Indeed, the parental and mCherry control BT lung cancer cells failed to form colonies in agarose even when cultured for ~8 weeks. By contrast, the *PIK3CA*^{H1047R} or M⁺AKT1 expressing cells cloned with an efficiency of 1% and 1.4%, respectively, after three weeks. These data indicate that PI3 -kinase AKT signaling cooperates with *BRAF*^{V600E} in oncogenic transformation of cultured lung cancer cell lines.

The ability of BPT lung cancer cells to form colonies in agarose was assessed in the presence of various pathway-targeted inhibitors. Unlike BT cells, BPT cells are capable of anchorage-independent colony formation (Vehicle, Fig. 6C). However, when cultured in the presence of a MEK inhibitor, a class 1 PI3 -kinase inhibitor or an AKT inhibitor, colony formation was abolished even when cultured for 8 weeks (Fig. 6C) (31). These data emphasize the ability of PI3 -kinase AKT signaling to cooperate with *BRAF*^{V600E} in promoting the transformed phenotype on lung cancer cells.

***BRAF*^{V600E}/*PIK3CA*^{H1047R}/*TP53*^{Null} lung cancer cell lines are sensitive to combined pharmacological inhibition of RAF or PI3'-kinase pathway inhibition**

To assess the mechanism(s) of cooperation between *BRAF*^{V600E} and *PIK3CA*^{H1047R} on the behavior of BPT cells they were treated with various pathway-targeted inhibitors of *BRAF*^{V600E} or *PIK3CA*^{H1047R} signaling, either alone or in combination, at which time effects on cell viability or the cell division cycle were assessed (Figs. 7A–C).

As expected, single agent inhibition of MEK1/2 or class 1 PI3 -kinases effectively decreased cell proliferation. Moreover, the combination of these agents had the strongest anti-proliferative effects, demonstrating at least an additive effect particularly in the mid-range of

drug (Fig. 7A). Despite its potency *in vivo*, single agent AKT inhibition (MK-2206) was ineffective at preventing the growth of these cells (Fig. 7B) even at 5 μ M. Single agent ERK1/2 inhibition (SCH772984) also exerted a cytostatic effect, only decreasing cell viability at higher concentrations (>250nM) (32). However, combined ERK1/2 plus AKT inhibition displayed cooperativity such that concentrations of inhibitors that had no single agent effect had striking inhibitory effects on cell proliferation when combined (Fig. 7B), which was further confirmed by Crystal Violet staining (Supp. Fig. 6A).

To assess the effects of the various agents on the cell division cycle, BPT cells were incubated with the various agents either alone or in combination and then labeled with BrdU to assess S phase progression (Fig. 7C, see Table 1 for drug concentrations). Vehicle-treated cells displayed a high proliferative index with >75% of cells incorporating BrdU. As expected, single-agent blockade of MEK1/2, ERK1/2, PI3 -kinase or AKT led to decreased BrdU incorporation and increased the G1 population with the PI3 -kinase inhibitor most potent, the MEK and ERK inhibitors roughly equipotent and the AKT inhibitor least potent. Cells treated with combined MEK1/2 plus PI3 -kinase or ERK1/2 plus AKT inhibitors displayed the most profound effects on the cell division cycle in addition to displaying evidence of cell death as assessed by the number of non-adherent cells and cells with a sub-G1 DNA content (Fig. 7C and Table 2). Taken together, these data indicate that BRAF^{V600E} and PIK3CA^{H1047R} cooperatively regulate the cell division cycle and cell death *in vitro*.

BRAF^{V600E} and PIK3CA^{H1047R} likely regulate many biochemical processes in the cell to influence cell proliferation *in vitro* and tumorigenesis *in vivo*. To assess the molecular mechanism(s) of such oncogenic cooperation we employed reverse phase protein array (RPPA) analysis to quantify protein expression/modification in BPT cells treated with inhibitors (Fig. 7D). Triplicate cultures of BPT cells were treated with inhibitors of MEK1/2 (PD), ERK1/2 (SCH), class 1 PI3 -kinases (GDC) or AKT1-3 (MK) either alone or in combination as indicated (Fig. 7D). Prior to RPPA analysis, we confirmed that each of the agents had the anticipated biochemical effects (Supp. Fig. 6B). As expected, inhibition of MEK1/2 or ERK1/2 led to strongly diminished pERK1/2 and promoted a modest increase in pAKT. Inhibition of PI3 -kinases or AKT led to strongly diminished pAKT with no obvious effects on pERK. Finally, the combinations of inhibitors potentially suppressed both pERK1/2 and pAKT.

The triplicate samples were subject to RPPA analysis using antisera against >150 proteins or protein modifications (33, 34). Unsupervised hierarchical clustering of the data indicated that samples clustered based on the pathway inhibited such that MEKi or ERKi treated samples clustered together as did PI3Ki and AKTi treated samples (Fig. 7D and Supp. Fig. 7). Samples from cells treated with combined pathway inhibitors clustered separately from samples from cells treated with the various single agents with the samples from cells treated with combined MEK1/2 plus class PI3 -kinase showing the greatest separation.

RPPA analysis generated predictions with regards to the consequences of inhibition of BRAF^{V600E} or PIK3CA^{H1047R} signaling on regulators of cell proliferation, some of which were then validated in an independent sample set by immunoblotting (Fig. 7E and Supp. Fig. 8). As predicted by RPPA analysis, inhibition of MEK1/2 + ERK1/2 signaling led to increased expression of the pro-apoptotic BCL-2 family protein BIM and decreased expression of c-MYC as well as cyclins D1 and A. Inhibition of PIK3CA^{H1047R}, but not AKT, also promoted BIM expression and inhibited c-MYC, cyclins D1 and A and led to elevated p27^{KIP1} expression and suppression of pRP-S6. Consistent with the lack of effect of MK-2206 against the proliferation of cultured BPT cell, we noted that inhibition of AKT had no single-agent effect on BIM, c-MYC, cyclins D1 or A, p4E-BP1 or pRP-S6 but largely extinguished phosphorylation of PRAS40, a known AKT substrate. Finally,

combined inhibition of both MEK and PI3 -kinases displayed additive effects on expression of c-MYC, cyclins D1 and A and BIM, the latter correlating with increased cleaved Caspases 3 (CC3) and 7 (CC7) that were also predicted by RPPA analysis. These analyses indicate the complexity with which these pathways cooperatively regulate apoptosis and the cell division cycle, which in turn influences tumor latency, burden and malignant progression. Although these experiments do not identify a single mechanism of BRAF^{V600E} - PIK3CA^{H1047R} cooperation in lung carcinogenesis, they suggest numerous areas of future investigation.

DISCUSSION

The mechanism(s) by which KRAS^{G12D} promotes lung carcinogenesis in humans and mice remain incompletely understood. However, here we demonstrate that two well-credentialed KRAS.GTP effectors, BRAF and PIK3CA, cooperate to mimic the effects of oncogenic KRAS^{G12D} in GEM models of lung cancer. Whereas BRAF^{V600E} expression elicits benign lung tumorigenesis, such tumors rarely progress to lung cancer, which contrasts with KRAS^{G12D}-initiated lung tumors (Fig. 7F). Unexpectedly, we noted that PIK3CA^{H1047R} failed to initiate lung tumorigenesis, even when combined with PTEN silencing, a result at odds with a previous report (9) (Fig. 7F). Indeed, no combination of heterozygous or homozygous *Pik3ca*^{lat} and *Pten*^{lox} initiated lung tumorigenesis, contrasting with the effects of a tetracycline inducible PIK3CA^{H1047R} transgene. It remains possible that strength of pathway activation, genetic background or the promoter system may influence these disparate results as suggested by similar observations in pancreatic cancer (24, 35). However, the lack of PIK3CA^{H1047R} effects in lung is consistent with the effects of PIK3CA^{H1047R} in ovarian epithelial cells (11). Furthermore, others have demonstrated that PI3 -kinase activation through PTEN silencing failed to elicit lung tumorigenesis (13). It is unclear whether the inability of PIK3CA^{H1047R} to initiate lung tumorigenesis will be predictive of anti-tumor effects of pharmacological inhibition targeting of PI3 -kinase in the clinic (9).

Despite its inability to initiate tumorigenesis, PIK3CA^{H1047R} cooperated with BRAF^{V600E} in dramatic fashion to promote lethal lung tumorigenesis, which occurred with short latency and complete penetrance (Fig. 7F). That PTEN silencing also cooperated with BRAF^{V600E}, albeit less strikingly, confirmed these observations indicating an important role for PI3 -lipid signaling. Although at early time points, BRAF^{V600E}/PIK3CA^{H1047R}-induced tumors were benign, six months post-initiation there was evidence of cancer progression in a manner reminiscent of KRAS^{G12D}. Finally, TP53 silencing in conjunction with combined BRAF^{V600E}/PIK3CA^{H1047R} expression, led to rapid lung cancer development, which showed signs of de-differentiation and epithelial-to-mesenchymal transition, hallmarks of advanced disease (36, 37, 38).

In conjunction with previous reports of the MEK1/2 and PI3 -kinase dependency of KRAS^{G12D}-induced lung tumors (39), the simplest explanation is that combined activation of RAF MEK ERK and PI3 -kinase AKT signaling cooperates to accelerate benign tumorigenesis and to promote malignant lung cancer progression. Although activation of BRAF and PI3 -kinase signaling accounts for much of the phenotype associated with KRAS^{G12D} expression, a role for other KRAS^{G12D} effectors remains possible since ~10% of KRAS^{G12D} initiated tumors display malignant progression whereas only ~3–8% of BRAF^{V600E}/PIK3CA^{H1047R} tumors do so (7). Indeed, since 10% of KRAS^{G12D}- or BRAF^{V600E}/PIK3CA^{H1047R}-initiated lung tumors display malignant progression, there must be additional stochastic genetic/epigenetic changes in benign tumor cells that promote malignant progression as emphasized by the effects of TP53 silencing on the progression of KRAS^{G12D}- or BRAF^{V600E}/PIK3CA^{H1047R}-initiated lung tumors.

The absence of malignant progression of BRAF^{V600E}-initiated lung tumors has been ascribed to a senescence-like proliferative arrest, which is due to feedback inhibition of PI3 - lipid production (10). This hypothesis is supported by our data since PIK3CA^{H1047R} expression enhanced the proliferative capacity of BRAF^{V600E}-initiated lung tumors. However, it remains unclear how PI3 -kinase signaling sustains the proliferation of these tumors. Previous data indicate cooperative regulation of cyclins cyclin-dependent kinase inhibitor expression by these pathways (40). Analysis of BPT cells suggests that the cell division cycle is indeed under the coordinate control of both BRAF^{V600E} and PIK3CA^{H1047R}. However, future experiments are required to determine which of the nodes of cell cycle regulation are essential to the observed cooperation.

BPT cells were sensitive to combined inhibition of BRAF^{V600E} and PIK3CA^{H1047R} with pathway-targeted agents. In general, single-agent inhibition of either pathway had inhibitory effects on the cell division cycle without promoting apoptosis. By contrast, combined pathway inhibition had stronger inhibitory effects on the cell cycle and also promoted cell death *in vitro* and *in vivo*. That AKT inhibition was without effect against lung tumors initiated by BRAF^{V600E} but potentially suppressed the cooperation between BRAF^{V600E} and PIK3CA^{H1047R} suggests a genotype-drug response phenotype with regards to AKT inhibition in GEM models. Whether these data will translate into the clinical utility of single or combined pathway-targeted interventions in humans with *BRAF* mutated lung cancer remains an open question. Whereas *KRAS* mutation is frequent in lung cancer, expression of BRAF^{V600E} or PIK3CA^{H1047R} accounts for a smaller percentage of NSCLC patients (2). Since mutated *KRAS* has proven an intractable pharmacological target, it will be interesting to determine whether combined pathway-targeted inhibition of RAF and PI3 -kinase signaling will promote regression of *KRAS* mutated lung cancers.

MATERIALS AND METHODS

Mice and Adenovirus delivery

Animal experiments were conducted in accordance with protocols approved by the UCSF Institutional Animal Care and Use Committee (IACUC). *BRAF^{CA}* (*Braf^{tm1Mmc}*), *Trp53^{lox}* (*Trp53^{tm1Bm}*), *PIK3CA^{lat-H1047R}* and *Pten^{lox}* mice were bred and genotyped as previously described (6, 11, 12, 14, 41). All mice were back-crossed onto the FVB/NJ genetic background for at least 10 generations. Experiments were performed using littermates as controls whenever possible. Stocks of Adenovirus encoding Cre recombinase were purchased from Viraquest (North Liberty, IA) or the University of Iowa, Gene Transfer Vector Core (29). Adenoviruses with cell specific expression of Cre recombinase were generously provided by Kate Sutherland and Anton Berns (NKI, Amsterdam) and purchased from the University of Iowa, Gene Transfer Vector Core (29). Intranasal instillation of adenovirus for infection of the mouse lung epithelium was performed as previously described (42). Tumor bearing mice were euthanized for analysis either at a pre-determined time point or when their body conditioning score (BCS) was 2 (15).

Histology and quantification of lung tumor burden

Lungs were removed, fixed in zinc buffered formalin (ZBS) and stored in 70%(v/v) ethanol prior to paraffin embedding. 6µm sections were stained with Hematoxylin and Eosin (H&E) on slides, scanned with an Aperio ScanScope scanner. Quantification of tumor number, size, and overall burden of individual lung sections was conducted using Aperio Spectrum ImageScope software. Overall tumor burden was calculated as (area of lung section occupied by tumor)/(total area of section) in µm².

Treatment of mice with pathway-targeted therapeutics

PD325901 (Hansun Trading Co.) was formulated in 0.5%(w/v) Hydroxy-Propyl-Methylcellulose (HPMT, Sigma) and administered daily (q.d) by oral gavage (po) at 12.5 mg/kg. MK-2206 (Merck) was formulated in 30%(w/v) Captisol (Ligand Technology, La Jolla, Ca.) and dosed at 120 mg/kg q.d. po. LGX-818 and BKM-120 (Novartis) were formulated in 0.5% carboxymethylcellulose (Sigma) plus 0.5% Tween 80 (Sigma) and dosed q.d. po at 30 mg/kg and 60 mg/kg, respectively. Mice were dosed with drug for pre-determined time points or until their body conditioning score (BCS) was 2, at which point they were euthanized for analysis (15).

Immunostaining of mouse lung tissue and immunoblotting

ZBS fixed sections of mouse lungs were subject to citrate-mediated antigen retrieval and then probed with: anti-pS473-AKT, anti-Vimentin, anti-PTEN (Cell signaling technology), anti-NKX2.1, anti-Ki67, anti-SP-C and anti-p63 (Santa Cruz Biotechnology). Immunoblotting was performed on 50µg of extracted protein and probed with antisera against various phospho- or backbone specific antisera as described. Immunoblots were quantified using an Odyssey FC system and Image Studio software.

Lung tumor cell isolation, culture and analysis

Single cell suspensions were generated from BRAF^{V600E}/TP53^{Null}- or BRAF^{V600E}/PIK3CA^{H1047R}/TP53^{Null}-induced lung cancers and cultured in Hams-F12/Glutamax media with 10%(v/v) fetal bovine serum. Following outgrowth, single cell-derived clones were isolated. Recombination of *BRAF*^{CA}, *Trp53*^{lox} and *Pik3ca*^{lat} alleles was verified by PCR (11). Expression of oncogenic BRAF^{V600E} was determined by immunoblotting with a mAb (VE1) specific to BRAF^{V600E} (43).

Cell proliferation was assessed in triplicate cultures of cells treated for 72 hours with: DMSO control, MEK1/2 inhibitor (PD325901, 15.6nM-1µM), ERK1/2 inhibitor (SCH772984, 7.8nM-5µM), AKT1-3 inhibitor (MK-2206, 80nM-5µM) or class 1 PI3 - kinase inhibitor (GDC-0941, 80nM-5µM) alone or in combination as indicated using a Cell Titre Glow assay (Promega). Cell cycle status was assessed in fixed floating and adherent cells stained with anti-BrdU-FITC (Becton-Dickinson) and propidium iodide (Sigma). Sorting of mCherry encoding ecotropic retroviruses was performed using a FACS-Calibur (Becton Dickinson) (44, 45). Anchorage-independent colony formation was performed by plating 5x10³ cells in 1.4%(w/v) Sea-Plaque low melting temperature agarose (Cambrex, Rockland, ME) and culturing them for three weeks at which time colony formation was enumerated using dissecting microscope.

Reverse Phase Protein Array (RPPA) Analysis

Reverse phase protein array (RPPA) analysis (Functional Proteomics Core Facility at M.D. Anderson Cancer Center) was performed as previously described (33, 34) and in supplementary information.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the members of the McMahon lab, especially David Dankort, Roch-Philippe Charles, Jillian Silva, Joseph Juan and J. Edward Van Veen for training, advice, guidance and support throughout this project. We thank Jane Gordon, Yunita Lim and Cynthia Cowdrey from the UCSF Laboratory for Cell Analysis and the Brain Tumor

Research Center respectively for assistance with microscopy, FACS analysis and processing of formalin fixed samples. We thank Kate Sutherland and Anton Berns (Netherlands Cancer Institute) for access to Adenovirus-Cre vectors, Frank McCormick (UCSF) and Xiaolin Nan (OHSU) for retroviral constructs, Meredith West and Sandy DeVries from the UCSF Radiation Therapy Oncology Group for use of the Aperio Scanner, Darrin Stuart and Emmanuelle Di Tomaso (Novartis) for LGX-818 and BKM-120 respectively, Lori Friedman (Genentech) for GDC-0941, Steven Townson and Ahmed Samatar (Merck) for MK-2206 and SCH772984. We thank Dr. Michael A. Davis and the M.D. Anderson Functional Proteomics Core Facility for performing and analyzing the RPPA analysis (supported by an NCI Cancer Center Support Grant, CA-16672). CT was supported by a Genentech Foundation Graduate Student Fellowship, SG was supported by a National Science Foundation Graduate Research Fellowship, EAC was supported by K08 CA137153 and by the Pancreatic Cancer Action Network, WAP was supported by project grants from the National Health and Medical Research Council of Australia and MM was supported by the National Cancer Institute (CA131261) and by Uniting Against Lung Cancer.

LITERATURE CITED

- Herbst RS, Heymach JV, Lippman SM. Lung cancer. *N Engl J Med*. 2008; 359:1367–80. [PubMed: 18815398]
- Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. *Cancer Cell*. 21:448, e2. [PubMed: 22439939]
- Network TCGAR. Diversity of Lung Adenocarcinoma Revealed by Integrative Molecular Profiling. *Nature*. 2013 Under Review.
- Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. *Mol Cancer Ther*. 2011; 11:485–91. [PubMed: 22135231]
- Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. *Oncogene*. 2005; 24:7455–64. [PubMed: 16288292]
- Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. *Genes Dev*. 2007; 21:379–84. [PubMed: 17299132]
- Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. *Cancer Res*. 2012; 72:3048–59. [PubMed: 22511580]
- Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. *Cancer Res*. 2007; 67:4933–9. [PubMed: 17510423]
- Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. *Nat Med*. 2008; 14:1351–6. [PubMed: 19029981]
- Courtois-Cox S, Genther Williams SM, Reczek EE, et al. A negative feedback signaling network underlies oncogene-induced senescence. *Cancer Cell*. 2006; 10:459–72. [PubMed: 17157787]
- Kinross KM, Montgomery KG, Kleinschmidt M, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. *J Clin Invest*. 2012; 122:553–7. [PubMed: 22214849]
- Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. *PLoS Biol*. 2003; 1:E59. [PubMed: 14691534]
- Iwanaga K, Yang Y, Raso MG, et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. *Cancer Res*. 2008; 68:1119–27. [PubMed: 18281487]
- Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes Dev*. 2001; 15:3243–8. [PubMed: 11751630]
- Ullman-Cullere MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. *Lab Anim Sci*. 1999; 49:319–23. [PubMed: 10403450]
- Dankort D, Curley DP, Carlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet*. 2009; 41:544–52. [PubMed: 19282848]

17. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. *Nat Struct Mol Biol.* 2004; 11:1192–7. [PubMed: 15543157]
18. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. *Mol Cancer Ther.* 2010; 9:1956–67. [PubMed: 20571069]
19. Halilovic E, She QB, Ye Q, et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. *Cancer Res.* 70:6804–14. [PubMed: 20699365]
20. Wee S, Jagani Z, Xiang KX, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. *Cancer Res.* 2009; 69:4286–93. [PubMed: 19401449]
21. Drahl C. LGX818, Made To Fight Melanoma. *Chemical & Engineering News.* 2013; 91:14.
22. Koul D, Fu J, Shen R, et al. Antitumor activity of NVP-BKM120—a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. *Clin Cancer Res.* 2011; 18:184–95. [PubMed: 22065080]
23. Hofmann I, Weiss A, Elain G, et al. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. *PLoS One.* 2012; 7:e44146. [PubMed: 22952903]
24. Collisson EA, Trejo CL, Silva JM, et al. A central role for RAF-->MEK-->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. *Cancer Discov.* 2012; 2:685–93. [PubMed: 22628411]
25. Kissil JL, Walmsley MJ, Hanlon L, et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. *Cancer Res.* 2007; 67:8089–94. [PubMed: 17804720]
26. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. *Nature.* 2009; 462:104–7. [PubMed: 19847165]
27. Nikitin AY, Alcaraz A, Anver MR, et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. *Cancer Res.* 2004; 64:2307–16. [PubMed: 15059877]
28. Livet J, Weissman TA, Kang H, et al. Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. *Nature.* 2007; 450:56–62. [PubMed: 17972876]
29. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. *Cancer Cell.* 2011; 19:754–64. [PubMed: 21665149]
30. Xu X, Rock JR, Lu Y, et al. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. *Proc Natl Acad Sci U S A.* 2012; 109:4910–5. [PubMed: 22411819]
31. Raynaud FI, Eccles SA, Patel S, et al. Biological properties of potent inhibitors of class I phosphatidylinositol 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. *Mol Cancer Ther.* 2009; 8:1725–38. [PubMed: 19584227]
32. Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. *Cancer Discov.* 2013
33. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. *Pigment Cell Melanoma Res.* 2011; 25:248–58. [PubMed: 22171948]
34. Gopal YN, Deng W, Woodman SE, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. *Cancer Res.* 2010; 70:8736–47. [PubMed: 20959481]
35. Eser S, Reiff N, Messer M, et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. *Cancer Cell.* 2013; 23:406–20. [PubMed: 23453624]
36. Snyder EL, Watanabe H, Magendantz M, et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. *Mol Cell.* 2013; 50:185–99. [PubMed: 23523371]
37. Winslow MM, Dayton TL, Verhaak RG, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. *Nature.* 2011; 473:101–4. [PubMed: 21471965]
38. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell.* 2009; 139:871–90. [PubMed: 19945376]

39. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. *Cell*. 2007; 129:957–68. [PubMed: 17540175]
40. Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon M. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. *Mol Cell Biol*. 2004; 24:10868–81. [PubMed: 15572689]
41. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. *Nat Genet*. 2001; 29:418–25. [PubMed: 11694875]
42. Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh MJ. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. *J Clin Invest*. 1998; 102:184–93. [PubMed: 9649572]
43. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. *Acta Neuropathol*. 2011; 122:11–9. [PubMed: 21638088]
44. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. *Gene Ther*. 2000; 7:1063–6. [PubMed: 10871756]
45. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. *Genes Dev*. 1998; 12:2997–3007. [PubMed: 9765202]

Figure 1. PI3 -kinase pathway activation is insufficient to initiate tumorigenesis in the mouse lung

A: Lungs of mice of the indicated genotypes were infected with Ad-Cre and monitored for three or 12 months as indicated at which time they were euthanized and their lungs processed for H&E staining. Representative H&E-stained tissue sections from *Pik3ca^{lat/lat}* (left) or *Pik3ca^{lat/lat}; Pten^{lox/lox}* (middle) animals euthanized 6 months after infection. *BRaf^{CA}* mice analyzed 12 weeks following Ad-Cre initiation are presented as a positive control (right).

B–U: Mouse lung sections from control (uninfected) or mice of the indicated genotypes treated as described in A were stained with DAPI, antisera against phospho-(p)-AKT or Ki67 as indicated. Insets indicate higher magnification of regions of airway hyperplasia.

Figure 2. PIK3CA^{H1047R} accelerates lung tumorigenesis initiated by BRAF^{V600E}

A: *BRAF^{CA}* and *BRAF^{CA}; Pik3ca^{lat}* mice were infected with Ad-Cre and monitored prospectively over ~120 days. Mice were euthanized at end-stage per IACUC regulations and a Kaplan-Meier survival curve was plotted.

B: *BRAF^{CA}* and *BRAF^{CA}; Pik3ca^{lat}* mice were infected with 10^7 pfu Ad-Cre to initiate expression of BRAF^{V600E} either alone or in combination with PIK3CA^{H1047R}. Mice were euthanized three weeks later with lungs processed for H&E staining. Scale bar = 100 μm .

C: Tumor number, size and burden were calculated as described in Materials and Methods in mice carrying either BRAF^{V600E} or BRAF^{V600E}/PIK3CA^{H1047R} expressing tumors.

Figure 3. PTEN silencing accelerates BRAF^{V600E}-initiated lung tumorigenesis

A: Mice of the indicated genotypes were infected Ad-Cre and euthanized four weeks later for analysis of tumor burden, which was quantified as described previously. Scale bars represent 100 μ M.

B: Lung tumors arising in *BRAF^{CA}* or *BRAF^{CA}; Pten^{lox/lox}* mice were stained with antisera against PTEN.

Figure 4. Pharmacological inhibition of PI3 K/AKT and MAPK signaling inhibits growth of BRAF^{V600E}/PIK3CA^{H1047R} tumors

A: BRAF^{V600E} or BRAF^{V600E}/PIK3CA^{H1047R} expressing lung tumors were initiated in mice of the appropriate genotype using Ad-Cre. Two weeks later mice were dosed for a further four weeks with vehicle control, MK-2206 or PD325901 as described in Materials and Methods at which time mice were euthanized and lungs prepared for H&E staining. Scale bar represents 500μm.

B: The effects of MK-2206 or PD325901 on lung tumor number, size and overall burden in mice bearing BRAF^{V600E} or BRAF^{V600E}/PIK3CA^{H1047R} expressing lung tumors was estimated as described in Materials and Methods. ** represents *p* values less than or equal to 0.005.

C&D: Lung tumors were initiated in *BRAF^{CA}; Pik3ca^{lat}* mice and five weeks later they were either untreated or treated with inhibitors of BRAF^{V600E} (LGX-818) or class 1 PI3 -kinases (BKM-120) either alone or in combination as indicated. Mice were euthanized when they developed end-stage disease and this was used to calculate a Kaplan-Meier survival curve (C). In addition, the weight of every mouse in each group was measured and normalized to its starting weight, which was set at 100%, and the average normalized weight of all mice in a treatment group was used to assess their response to treatment (D).

E&F: Lung tumor burden in *BRAF^{CA}; Pik3ca^{lat}* treated as described in C&D was assessed by H&E staining of lung tumor sections. Lung tumor specimens from untreated or BKM-120 treated mice came from mice with end-stage disease whereas the specimens from the LGX-818 or combined LGX-818 plus BKM-120 treatments were derived from mice at

the end of the 4 week dosing schedule. *** represents a p value of 0.0003, **** represents a p value of less than 0.0001.

Figure 5. PIK3CA^{H1047R} promotes malignant progression of BRAF^{V600E}-initiated lung tumors
A: BRAF^{V600E} or BRAF^{V600E}/PIK3CA^{H1047R} expressing lung tumors were initiated in mice of the appropriate genotype using Ad-Cre with mice monitored for 25 weeks at which time they were euthanized and their lungs processed for H&E staining. Scale bar represents 50μm. Lung tumor number, size and overall burden was assessed as described in Materials and Methods.

B: The grade of BRAF^{V600E} or BRAF^{V600E}/PIK3CA^{H1047R} expressing lung tumors was assessed on a 4 point scale using the grading criteria described in Supplemental Figure S3.

Figure 6. Ectopic expression of either activated PIK3CA or AKT1 promotes anchorage independent growth to BRAF^{V600E}; TP53^{null} lung cancer derived cells

A: BRAF^{V600E}/TP53^{null} lung cancer derived cells were infected with retroviruses as described in the text. Cell extracts were analyzed by immunoblotting as indicated. Quantification of blots is included as Supp. Fig. 8A.

B: Anchorage-independent growth of BRAF^{V600E}/TP53^{null} lung cancer cells engineered to express mCherry, PIK3CA^{H1047R} or M+AKT1 was quantified over three weeks.

C: BRAF^{V600E}/PIK3CA^{H1047R}/TP53^{null} lung cancer cells were plated in soft agar in the absence (vehicle) or presence of inhibitors of MEK1/2 (1μM PD325901), class 1 PI3 -kinase

(5 μ M GDC-0941) or AKT (5 μ M MK-2206). Anchorage-independent growth was assessed over three weeks.

Figure 7. Cooperative effects of combined pharmacological blockade BRAF^{V600E} and PIK3CA^{H1047R} signaling on BRAF^{V600E}/PIK3CA^{H1047R}/TP53^{null} lung cancer derived cells
A&B: BRAF^{V600E}/PIK3CA^{H1047R}/TP53^{null} lung cancer cells were treated with a range of concentrations of MEKi (PD325901), PI3 Ki (GDC-0941), ERKi (SCH772984) or AKTi (MK-2206) either alone or in the indicated combinations for 72 hours when cell viability was measured using a Cell-Titre-Glo assay (Promega) and normalized to zero concentration values.
C: BRAF^{V600E}/PIK3CA^{H1047R}/TP53^{null} lung cancer cells were treated with inhibitors of MEK1/2, ERK1/2, AKT1-3 or class 1 PI3 -kinases either alone or in the indicated combinations for 24 hours at concentrations listed in Table S1. Cell cycle status was assessed by FACs analysis of cells labeled with BrdU and Propidium Iodide.
D: Unsupervised clustering of RPPA analysis of cell extracts derived from cells treated in biological triplicates with inhibitors of MEK1/2 (PD), ERK1/2 (SCH), AKT1-3 (MK) or class 1 PI3 -kinases (GDC) either alone or in the indicated combinations for 24 hours. Full dataset is included as Supp. Fig. 7 and an Excel file.
E: Cell extracts prepared from BPT lung cancer cells treated with inhibitors of MEK1/2 (PD), ERK1/2 (SCH), AKT1-3 (MK) or class 1 PI3 -kinases (GDC) either alone or in the indicated combinations for 24 hours were analyzed by immunoblotting and quantified against -actin (Supp. Fig. 8B).

F: Mutationally activated KRAS^{G12D} promotes lung hyperplasia (H) then benign adenomas (BA), some of which progress to non-small cell lung cancers (NSCLC). Similarly initiated expression of BRAF^{V600E} leads to more rapid and numerous hyperplasia and benign adenomas but without progression to NSCLC, most likely due to a senescence-like growth arrest. Although PIK3CA^{H1047R} fails to initiate pathology in the lung, when combined with BRAF^{V600E}, it promotes rapid emergence of hyperplasias and benign adenomas, some of which progress to NSCLC. At the molecular level, BRAF^{V600E} cooperates with PIK3CA^{H1047R} to regulate the cell division cycle and suppress apoptosis.